Skip to main content
. 2024 Dec 26;17(1):39. doi: 10.3390/cancers17010039

Figure 1.

Figure 1

Molecular types of assessed breast carcinomas—Line I—Luminal A type (ER ≥ 1%; PR ≥ 20%; HER2 ≤ 10%; Ki-67 < 14%); Line II—Luminal B type+HER2+ (ER ≥ 1%; PR variable; HER2 > 10%; Ki-67 > 20%); Line III—HER2 enriched (ER < 1%; PR < 20%; HER2 > 10%; Ki-67 > 20%); Line IV—Triple-Negative (ER < 1%; PR < 20%; HER2 ≤ 10%; Ki-67 > 30%); Ob-X40 (all pictures).